Champions Oncology, Inc. provided revenue guidance for the fiscal year 2022. The company position is to achieve 15% - 20% revenue growth guidance for fiscal 2022. The company positioned for continued revenue growth while the company expand the company's other revenue streams and platforms. The company project the company's revenue growth to offset the additional R&D spend so that the company's operating results remain positive over the long term.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.53 USD | -2.58% | +0.22% | -19.39% |
03-15 | Tranche Update on Champions Oncology, Inc.'s Equity Buyback Plan announced on April 5, 2023. | CI |
03-13 | Craig-Hallum Downgrades Champions Oncology to Hold From Buy | MT |
1st Jan change | Capi. | |
---|---|---|
-19.39% | 61.58M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.18% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- CSBR Stock
- News Champions Oncology, Inc.
- Champions Oncology, Inc. Provides Revenue Guidance for the Fiscal Year 2022